贝林妥欧单抗与奥英妥珠单抗治疗儿童B细胞前体急性淋巴细胞白血病:SEHOP白血病工作组回顾性研究
该回顾性研究分析了29例接受贝林妥欧单抗、奥英妥珠单抗或两者联合治疗的儿童ALL患者数据。在首次或第二次完全缓解阶段,两种抗体有助于降低微小残留病和/或避免进一步毒性化疗直至干细胞移植。
要点
- 首次或第二次完全缓解阶段使用可降低微小残留病并桥接移植。
- 6例发生3级可逆性非血液学毒性。
研究设计与样本
- 西班牙儿科血液肿瘤学会白血病工作组回顾性分析29例接受贝林妥欧单抗、奥英妥珠单抗或两者联合治疗的儿童ALL患者数据。
主要发现
- 在首次或第二次完全缓解阶段,两种抗体有助于降低微小残留病和/或避免进一步毒性化疗直至干细胞移植。
- 6例患者发生3级可逆性非血液学毒性。
临床怎么用
- 在重度预处理复发儿童ALL中可考虑贝林妥欧单抗或奥英妥珠单抗作为桥接移植或降低微小残留病的替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use with blinatumomab, inotuzumab or both. The complete remission (CR) rate in a heavily pretreated population with overt relapse was 47·6%. At earlier stages (first/second CR), both antibodies represented a useful tool to reduce minimal residual disease, and/or avoid further toxic chemotherapy until stem cell transplantation. Six patients developed grade 3 reversible non-haematological toxicity. The 12-month overall survival and event-free survival rates were 50·8 ± 26·4% and 38·9 ± 25·3% with blinatumomab, 45·8 ± 26% and 27·5 ± 25% with inotuzumab.
引用
- Fuster JL, Molinos-Quintana A, Fuentes C, et al. Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP). Br J Haematol. 2020. PMID: 32314348. doi:10.1111/bjh.16647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。